GlassScriptPhysician profile
Calvin Abro
NPI 1346765724
$8,925.01
in general payments reported to CMS, 2019-2025
66 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2021: $73.40 · 2022: $13.76 · 2023: $2,068 · 2024: $5,381 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,493 · Education: $1,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,492.96 |
| Education | $1,105.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $937.75 | 2023-2025 | Darzalex, Tecvayli, Rybrevant |
| Pfizer INC. | $505.32 | 2023-2025 | |
| Incyte Corporation | $438.92 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Merck Sharp & Dohme LLC | $428.55 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $413.62 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $383.83 | 2023-2025 | Opdivo, Reblozyl, Krazati |
| Astrazeneca Pharmaceuticals LP | $366.72 | 2023-2025 | Enhertu, Lynparza, Tagrisso |
| Seagen INC. | $332.09 | 2021-2023 | Adcetris, Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $307.36 | 2023-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Abbvie INC. | $302.57 | 2024-2025 | |
| Tempus Ai, INC | $284.73 | 2024-2025 | Xt Cdx |
| Regeneron Healthcare Solutions, INC. | $276.25 | 2023-2024 | Libtayo |
| Glaxosmithkline, LLC. | $271.02 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Astellas Pharma US INC | $260.68 | 2023-2025 | Xtandi, Padcev |
| Daiichi Sankyo INC. | $256.68 | 2024-2025 | Enhertu, Injectafer, Datroway |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $247.94 | 2023-2025 | Reblozyl, Pomalyst |
| Sobi, INC | $243.15 | 2023-2025 | |
| Genzyme Corporation | $182.74 | 2023-2025 | |
| Exelixis INC. | $180.46 | 2024-2025 | Cabometyx |
| Medtronic, INC. | $175.00 | 2024 | Osteocool Rf Ablation System |
| Genentech USA, INC. | $142.68 | 2024-2025 | Venclexta, Polivy, Itovebi |
| Stemline Therapeutics INC. | $127.58 | 2023-2024 | Orserdu |
| Array Biopharma INC | $116.89 | 2023-2024 | Lorbrena, Braftovi, Mektovi |
| Eisai INC. | $101.59 | 2024-2025 | |
| Emd Serono, INC. | $93.61 | 2023-2024 | |
| Adaptive Biotechnologies Corporation | $91.70 | 2024 | Clonoseq |
| Servier Pharmaceuticals LLC | $90.75 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.07 | 2024-2025 | |
| Kyowa Kirin, INC. | $74.71 | 2023-2024 | Poteligeo |
| Ipsen Biopharmaceuticals, INC | $73.67 | 2023-2024 | Somatuline Depot, Onivyde, Tazverik |
| Shield Therapeutics INC | $69.00 | 2023 | Accrufer |
| Pharmaessentia USA Corporation | $59.77 | 2024 | Besremi |
| Pharmacyclics LLC, An Abbvie Company | $56.19 | 2023 | Imbruvica, Epkinly |
| Jazz Pharmaceuticals INC. | $54.09 | 2023-2024 | |
| Deciphera Pharmaceuticals INC. | $51.30 | 2023-2024 | Qinlock, Tgct |
| Kite Pharma, INC. | $50.19 | 2023-2025 | Yescarta |
| Sumitomo Pharma America, INC. | $43.72 | 2024-2025 | Orgovyx |
| Karyopharm Therapeutics INC. | $42.49 | 2023 | Xpovio |
| Tersera Therapeutics LLC | $39.66 | 2024 | Zoladex |
| Agios Pharmaceuticals, INC. | $39.64 | 2024 | Pyrukynd |
| Taiho Oncology, INC. | $39.37 | 2024 | |
| Coherus Oncology, INC. | $38.41 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $37.53 | 2024-2025 | Monoferric, Cosela |
| Myriad Genetic Laboratories, INC. | $30.28 | 2024 | Precisetumor |
| Acrotech Biopharma INC. | $28.81 | 2024 | Ryzneuta |
| Amgen INC. | $28.67 | 2022-2023 | Blincyto, Kyprolis |
| Napo Pharmaceuticals INC | $28.35 | 2024 | Gelclair Concentrated Oral Gel |
| Adc Therapeutics America, INC. | $28.19 | 2025 | |
| Lilly USA, LLC | $28.02 | 2024 | Jaypirca, Verzenio |
| Biocon Biologics INC | $24.29 | 2024 | Fulphila |
| G1 Therapeutics, INC. | $24.26 | 2023 | Cosela |
| Foundation Medicine, INC. | $24.24 | 2023 | |
| Amneal Pharmaceuticals LLC | $23.51 | 2024 | Neupogen, Avastin, Neulasta |
| Rigel Pharmaceuticals, INC. | $22.92 | 2024 | Tavalisse, Rezlidhia |
| Accord Healthcare, INC. | $22.50 | 2023 | |
| Beone Medicines USA, INC. | $21.52 | 2025 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $19.74 | 2024 | Sancuso |
| Beigene USA, INC. | $18.86 | 2023 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $18.54 | 2024 | |
| Mirati Therapeutics, INC. | $17.51 | 2023 | Krazati |
| Immunogen, INC. | $17.11 | 2023 | Elahere |
| Puma Biotechnology, INC. | $16.57 | 2025 | |
| Alexion Pharmaceuticals, INC. | $15.78 | 2023 | Ultomiris |
| Novo Nordisk INC | $13.87 | 2019 | |
| Boston Scientific Corporation | $13.48 | 2025 | Spaceoar Vue System - 10ml |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Abro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.